A new CRISPR-based one-off procedure that lowers "bad" cholesterol has been approved to enter Phase I human trial. If ...

Last year, a ten-month-old baby in the US was the first person in the world to have their rare genetic disease effectively ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $54.65, marking a -1.57% move from the previous day. This move lagged the S&P 500's daily gain of 0.5%. On the other hand, the ...

And, if all goes well, over the next five years as well.

US biotech start-up Aurora Therapeutics has launched with $16 million in seed funding from Menlo Ventures, aiming to turn one-off CRISPR gene-editing successes into a scalable model for rare diseases.

CRISPR biosensors are transforming healthcare by detecting biomarkers at attomolar sensitivity, enabling real-time health monitoring through wearable patches and implantable sensors. They continuously ...

In this article, we will take a look at the Top 10 CRISPR Stocks to Buy Now. Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Stocks Going Wild. Crispr Therapeutics rallied for a second day on Wednesday, adding 9.6 percent to close at $60.08 apiece, tracking the rally in ...

Menlo Ventures has made a $16 million bet that the “baby KJ” custom CRISPR therapy success story is repeatable. The funding has enabled CRISPR co-inventor Jennifer Doudna, Ph.D., and baby KJ scientist ...

Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it’s one of her top holdings. 10 stocks we like ...

Tobi is a crypto writer at Investopedia. He aims to simplify the complex concepts of blockchain and cryptocurrencies for the masses. Julie Bang/ Investopedia More people need better medicines, and ...

Even though broader equities have been highly volatile this year, it's still a good idea to invest in stocks for a straightforward reason. Holding shares of top companies for five years and beyond ...